Prof. Dr. Hakan BOZKAYA

Deneyim

MEMORIAL ANKARA HASTANESİ

Gastroenteroloji Uzmanı
2016 - Halen, Ankara/Türkiye

LIV HOSPTAL

Gastroenteroloji Uzmanı
2015 - 2016, Ankara/Türkiye

ANKARA ÜNİVERSİTESİ

Gastroenteroloji Uzmanı
1996 - 2015, Ankara/Türkiye

TULANE ÜNIVERSITY

Gastroenteroloji ve Hepatoloji Bölümü
1995 - 1996, New Orleans/ABD

Eğitim

ANKARA ÜNİVERSİTESİ TIP FAKÜLTESİ

Gastroenteroloji Uzmanlık Eğitimi
1992 - 1995 , Ankara/Türkiye

ANKARA ÜNİVERSİTESİ TIP FAKÜLTESİ

İç Hastalıkları Uzmanlık Eğitimi
1988 - 1992 , Ankara/Türkiye

İSTANBUL ÜNİVERSİTESİ TIP FAKÜLTESİ

Tıp Doktoru Eğitimi
1981 - 1987 , İstanbul/Türkiye

Bilimsel Yayınları

1- Bozkaya H, Ayola B and Lok ASF. High rate of mutations in the hepatitis B core gene during the immune clearance phase of chronic hepatitis B virus infection. Hepatology 24;1:32-37, 1996.

2- Bozkaya H, Akarca US, Ayola B, Lok ASF. High degree of conservation in the hepatitis B virus core gene during the immune tolerant phase in perinatally acquired chronic hepatitis B virus infection. Journal of  Hepatology 26;3:580-516, 1997.

3- Bozdayi AM, Bozkaya H, Turkyilmaz A, Aslan N, Verdi H, Kence A, Uzunalimoglu O. Polymorphism of precore region of hepatitis B virus DNA among patients with chronic HBV infection in Turkey. Infection 1999 Nov-Dec;27(6):357-60

4- Akbay A, Cinar K, Uzunalimoglu O, Eranil S, Yurdaydin C, Bozkaya H, Bozdayi M. Serum cytotoxin and oxidant stress markers in N-acetylcysteine treated thioacetamide hepatotoxicity of rats. Hum Exp Toxicol 1999 Nov;18(11):669-76

5- Celik T, Uzbay T, Cinar K, Bozkaya H, Uzunalimoglu O, Yurdaydin C. Combination treatment of hepatic encephalopathy due to thioacetamide-induced fulminant hepatic failure in the rat with benzodiazepine and opioid receptor antagonists. J Hepatol 1999 Nov;31(5):880-6

6- Arıca, A., Şengezer, T., Bozdayı, A.M., Bozkaya, H., Üçgül, E., Dinçol, D., Uzunalimoğlu, Ö.: Prevalence Of Hepatitis-G Virus And Hepatitis-C Virus Infection In Patients With Non- odgkin's Lymphoma Prevalence of hepatitis-G virus and hepatitis-C virus infection in  patients with non-Hodgkin's lymphoma.  Med Oncol. 2000 ;17(2):123-126

7- Bozdayı, A.M., Uzunalimoglu,Ö.,Aslan,N., Bozkaya, H., Türkyilmaz, A.R., Kayhan,B., Sahin, T., Sivri, B., Uygun, A., Altiok, A., Çetinkaya, H., Karayalçin, S., Yurdaydın,  C.: The Influence Of Viral Load And Alanine Aminotransferase On The Viral Genetic Heterogeneity  In Patients With Chronic Hepatitis C Virus Infection. Intervirology 2000;43(1):61-6

8- Bozkaya,H.,Bozdayı, A.M., Türkyılmaz,A., Sarıoğlu, M., Çetinkaya,H.,Çınar, K., Köse, K., Yurdaydın, C., Uzunalimoğlu, Ö:  Circulating IL-2, IL-10 and TNF alpha in chronic Hepatitis B: their relations to HBeAg status and the activity of liver disease.Hepatogastroenterology, 2000, 47:1675-1679

9- Bozkaya,H., Bozdayı, A.M., Aslan, N., Çetinkaya,H., Akdoğan, M., Senturk, H.,Akkız, H., yurdaydın, C., Karayalçın, S.,  Uzunalimoğlu,Ö.: Cytokine production during interferon      treatment in patients with chronic hepatitis C.  Infection 2000;28:309-313

10- Bozdayı, A.M., Bozkaya, H., Türkyılmaz, A.R., Sarıoğlu, M., Çetinkaya,H., Karayalçın, S., Yurdaydın, C., Uzunalimoğlu, Ö.: Nucleotide divergences in the core promoter and precore region of genotype D hepatitis B virus in patients with persistently elevated or normal ALT levels. J Clin Virol. 2001 Apr;21(1):91-101.

11-  Ö. Uzunalimoğlu, C. Yurdaydın, H. Çetinkaya, H. Bozkaya, T. Şahin, S. Çolakoğlu, E. Tankut, M. Sarıoğlu, S. Özenirler, H. Akkız, N. Tözün, H. Değertekin, A. Ökten. Risk factors for hepatocellular carcinoma in Turkey. Dig Dis Sci 2001 May;46:5:1022-8

12- Bozkaya H, Yurdaydin C, Toruner M, Arat M, Bozdayi AM, Erekul S, Cinar K, Koc H, Uzunalimoglu O. Remission of severe aplastic anemia associated with hepatitis B virus infection after viral clearence:potential role of lamivudine. Dig Dis Sci 2002 ;47 :1782-5

13- Yurdaydin C, Bozkaya H, Gurel S, Tillmann HL, Aslan N, Okcu-Heper A, Erden E, Yalcin K, Ilıman N, Uzunalimoglu O, Manns MP, Bozdayi AM. Famciclovir treatment in chronic hepatitis D. J of  Hepatology 2002; 37:266-71.

14- Bozkaya H, Yurdaydin C, Bozdayi AM,Erkan O, Karayalcin S, Uzunalimoglu O. Oral ganciclovir for treatment of lamivudine resistant hepatitis B virus infection: a pilot study. Clin Infect Dis 2002; 35:960-5

15- Ebru Serinoz,  Murat Varli, Esra Erden, Kubilay Cinar, Aydan Kansu, Ozden Uzunalimoglu, Cihan Yurdaydin, Hakan Bozkaya. Nuclear localization of HBcAg and its relations to hepatocyte proliferation and viral load. J Clin Gastroenterol. 2003Mar;36(3):269-72.

16- Bozdayi AM, Uzunalimoglu O, Turkyilmaz AR, Aslan N, Sezgin O, Sahin T, Bozdayi G, Cinar K, Pai SB, Pai R, Bozkaya H, Karayalcin S, Yurdaydin C, Schinazi RF. YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine. J Viral Hepat. 2003 Jul;10(4):256-265.

17- Senturk H, Ersoz G, Ozaras R, Kaymakoglu S, Bozkaya H, Akdogan M, Mert A, Bozdayi M, Tabak F, Yenice N, Ozbay G. Interferon-alpha2b induction treatment with or without ribavirin in chronic hepatitis C: a multicenter, randomized, controlled trial. Dig Dis Sci. 2003; 48: 1124-9.

18- Yalcin K, Degertekin H, Yurdaydin C, Bozdayi M, Bozkaya H.

The role of HBeAg seroconversion in acute exacerbation of liver disease with termination of hepatitis B and D virus infection in a chronic hepatitis D patient during alpha-interferon therapy.
Eur J Gastroenterol Hepatol. 2003 Jul;15(7):819-23.

19-Erden A, Bozkaya H, Turkmen SI, et al. Duodenal angiodysplasia: MR angiographic evaluation in a case report. Abdom Imaging 2003

20- Bozkaya H, Bektas M, Metin O, et al. Screening for hemochromatosis in Turkey. Dig Dis Sci 2004;49: 444-449

21- Yurdaydin C, Bozkaya H,.et al. Lamivudine vs Lamivudine+interferon in the treatment of HbeAg-negative chronic hepatitis B. J Viral Hepatitis 2004 (in press)

22- Bozdayi et al. HBV, HCV and HDV genoypes in Turkish population. Antiviral research 2004; July 15

23- Akbiyik F, Day R, Bozkaya H, Demirpence E. Ligand and species dependent activation of PPAR-alpha. Cell Physiol Biochem 2004;14:269-76

24-Akbiyik et al. Ligand induced expression of PPAR-alpha and activity of  fatty acid oxidation enzymes in fatty liver. Eur J Clin Invest 2004:34:429-35

25- Tanju S, Erden A, Ceyhan K, et al. Contrast-enhanced MR Angiography of Benign Regenerative nodules following TIPS shunt procedure in Budd-Chiari syndrome.
Turk J Gastroenterol. 2004 Sep;15(3):173-177.

26-Karavelioğlu D, Koytak ES, Bozkaya H, et al. Lichen planus and HCV infection in Turkish patients. Turk J Gastroenterol. 2004

27-Aslan N, Bozdayı AM, Çetinkaya H, et al. The mutations in ISDR of NS5A gene are not associated with response to interferon treatment in Turkish patients with chronic hepatitis C virus genotype 1b infection.
Turk J Gastroenterol. 2004 Mar;15(1):21-6.

28- Bozkaya H. Breaking the tolerance or the virus?
Turk J Gastroenterol. 2004 Mar;15(1):1-3.

29-Bozdayi AM, Aslan N, Bozdayi G. Molecular epidemiology of hepatitis B, C and D viruses in Turkish patients. Arch Virol. 2004 Jul 15

30-Yurdaydın C, Bozkaya H, Çetinkaya H, et al. Lamivudine vs lamivudine and interferon combination treatment of HBeAg(-) chronic hepatitis B.
J Viral Hepat. 2005 May;12(3):262-8.

31-Çelik T, Gören MZ, Çınar K, et al. Fatigue of cholestasis and the serotoninergic neurotransmitter system in the rat.
Hepatology. 2005 Apr;41(4):731-7.

32- Erkan Ö, Bozdayi AM, Dişibetaz S, et al. Thrombophilic gene mutations in cirrhotic patients with portal vein thrombosis.
Eur J Gastroenterol Hepatol. 2005 Mar;17(3):339-43.

33- Bozkaya H, Yurdaydın C, Idilman R, et al. Lamivudin treatment of patients with low level viremia. Anti-viral Therapy 2005.

34- Verdi, Sare Koytak, et al. Peroxisome Proliferator-Activated Receptor alpha L162V Polymorphism in Nonalcoholic Steatohepatitis and Genotype 1 Hepatitis C Virus-Related Liver Steatosis.
J Investig Med. 2005 Nov;53(7):353-9.

35- Varlı, Heper, Erden. P21 expression and its relation to disease activity and hepatocyte proliferation in chronic hepatitis B virus infection.
Turk J Gastroenterol. 2005 Mar;16(1):12-6.

36- Celik G, Sen E, Ulger A, et al. Sarcoidosis caused by interferon therapy.
Respirology. 2005 Sep;10(4):535-40.

37- Endoscopic Management of Biliary Parasitic Diseases. Bektaş M, Dökmeci A, Cinar K, Halici I, Oztas E, Karayalcin S, Idilman R, Sarioglu M, Ustun Y, Nazligul Y, Ormeci N, Ozkan H, Bozkaya H, Yurdaydin C. Dig Dis Sci. 2009 Jun 10.

38- A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients. Idilman R, Kaymakoglu S, Oguz Onder F, Ahishali E, Bektas M, Cinar K, Pinarbasi B, Karayalcin S, Badur S, Cakaloglu Y, Mithat Bozdayi A, Bozkaya H, Okten A, Yurdaydin C. J Viral Hepat. 2009 Apr;16(4):279-85

39- PPAR-alpha L162V polymorphism in human hepatocellular carcinoma. Koytak ES, Mizrak D, Bektaş M, Verdi H, Arslan Ergül A, Idilman R, Cinar K, Yurdaydin C, Ersõz S, Karayalçin K, Uzunalimoğlu O, Bozkaya H. Turk J Gastroenterol. 2008 Dec;19(4):245-9.

40- Adjuvant therapeutic plasma exchange in liver failure: assessments of clinical and laboratory parameters. Bektas M, Idilman R, Soykan I, Soydan E, Arat M, Cinar K, Coban S, Tuzun A, Bozkaya H, Ormeci N, Ozden A. J Clin Gastroenterol. 2008 May-Jun;42(5):517-21.

41- Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. Yurdaydin C, Bozkaya H, Onder FO, Sentürk H, Karaaslan H, Akdoğan M, Cetinkaya H, Erden E, Erkan-Esin O, Yalçin K, Bozdayi AM, Schinazi RF, Gerin JL, Uzunalimoğlu O, Ozden A.

J Viral Hepat. 2008 Apr;15(4):314-21.

42- A pilot study of 2 years of interferon treatment in patients with chronic delta hepatitis. Yurdaydin C, Bozkaya H, Karaaslan H, Onder FO, Erkan OE, Yalçin K, Değertekin H, Bozdayi AM, Uzunalimoğlu O. J Viral Hepat. 2007 Nov;14(11):812-6.

43- Pegylated interferon-alpha plus taurine in treatment of rat liver fibrosis. Tasci I, Mas MR, Vural SA, Deveci S, Comert B, Alcigir G, Mas N, Akay C, Bozdayi M, Yurdaydin C, Bozkaya H, Uzunalimoglu O, Isik AT, Said HM. World J Gastroenterol. 2007 Jun 21;13(23):3237-44.

44- Effects of vitamin E treatment on peroxisome proliferator-activated receptor-alpha expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study.Yakaryilmaz F, Guliter S, Savas B, Erdem O, Ersoy R, Erden E, Akyol G, Bozkaya H, Ozenirler S. Intern Med J. 2007 Apr;37(4):229-35.

45- Antituberculous therapy-induced fulminant hepatic failure: successful treatment with liver transplantation and nonstandard antituberculous therapy. Idilman R, Ersoz S, Coban S, Kumbasar O, Bozkaya H. Liver Transpl. 2006 Sep;12(9):1427-30.

46- Cytotoxic CD4 T cells in viral hepatitis. Aslan N, Yurdaydin C, Wiegand J, Greten T, Ciner A, Meyer MF, Heiken H, Kuhlmann B, Kaiser T, Bozkaya H, Tillmann HL, Bozdayi AM, Manns MP, Wedemeyer H. J Viral Hepat. 2006 Aug;13(8):505-14.

47- Pulmonary alterations in patients with chronic HCV infection. Erturk A, Tokgonul AN, Capan N, Erturk H, Dursun AB, Bozkaya H. Dig Liver Dis. 2006 Sep;38(9):673-6. Epub 2006 Jun 21.

48- Hepatitis B core antigen expression pattern reflects the response to anti-viral treatment. Uzun Y, Bozkaya H, Erden E, Cinar K, Idilman R, Yurdaydin C, Uzunalimoglu O. J Gastroenterol Hepatol. 2006 Jun;21(6):977-81.

49- Long-term prognosis of nonalcoholic fatty liver disease: is pharmacological therapy actually necessary? Cinar K, Coban S, Idilman R, Tuzun A, Sarioglu M, Bektas M, Erden E, Bozkaya H, Ozden A. J Gastroenterol and Hepatol 2006; 21:169-73

50- Percutaneous transhepatic venoplasty: an alternative treatment for Budd-Chiari syndrome. Bahar K, Karayalçin S, Kaya M, Cetinkaya H, Bozkaya H, Yurdaydin C. Turk J Gastroenterol. 2002 Jun;13(2):83-8.

51-Aflatoxin exposure in viral hepatitis patients in Turkey. Mızrak D, Engin B, Onder FO, Yener B, Bektaş M, Biyikli Z, Idilman R, Çinar K, Karayalçin K, Ersöz S, Karayaşçın S, Ozden A, Yurdaydin C, Yazihan N, Ataoğlı H, Bozkaya H, Uzunalimoglu O. Turk J Gastroenterol 2009;20: 192-197

52- Quantitative HbsAg and HDV RNA levels in chronic delta hepatitis. Zachou K, Yurdaydin C, Drebber U, Dalekos GN, Erhardt A, Cakaloglu Y, Degertekin H, Gurel S, Zeuzen S, Bozkaya H, Sclaphoff V, Dienes HP, Bock TC, Manns MP, Wedemeyer H; HIDT-1 study group. Liver Int 2010 30(3):430-7

53- The charactersitics and clinical outcome of drug-induced liver injury: a single center experience. Idilman R, Bektas M, Cinar K, Toruner M, Cerit ET, Doganay B, Erden E, Bozkaya H, Bahar K, Karayalcin S, Soykan I, Palabıyıkoglu M, Cetinkaya H, Yurdaydin C, Dokmeci A, Ozden A. J Clin Gastroenterol 2010 44:128-32

54- Natural History and treatment of chronic delta hepatitis. Yurdaydin C, Idilman R, Bozkaya H, Bozdayi AM. J Viral Hepat 2010 17: 749-56.

55- Peginterferon plus adefovir versus either drug alone for hepatitis delta. Wedemeyer H, Yurdaydin C, Dalekos GN, Erhardt A, Cakaloglu Y, Degertekin H, Gurel S, Zeusem S, Zachou K, Bozkaya H, Koch A, Bock T, Dienes HP, Manns MP; HIDIT study group. N Eng J Med 2011 364:322-31

56- Serum connective tissue markers as predictors of advanced fibrosis in patients with chronic hepatitis B and D. Seven G, Karatayli SC, Köde SK, Yakut M, Kabacam G, Toruner M, Heper AO, Voelker M, Erden E, Bozdayi AM, Uzunalimoglu O, Bozkaya H, Yurdaydin C, Schuppan D. Turk J Gastroneterol 2011 22: 305-14

57- Anti-HDV immunoglobulin M tetsing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon alfa2a treatment. Mederacke I, Yurdaydin C, Dalekos GN, Bremer B, Erhardt A, Cakaloglu Y, Yalcin K, Gurel S, Zeuzem S, Zachou K, Bozkaya H, Dienes HP, Manns MP, Wedemeyer H; Hep-Net/International Delta Hepatitis study group. Antiviral Ther 2012; 17: 305-12

58- Renal function during treatment with adefovir plus peginterferon2a vs either drug alone in hepatitis B/D coinfection. Mederacke I, Yurdaydin C, Grobhenning A, Erhardt A, Cakaloglu Y, Yalcın K, Gurel S, Zeuzem S, Zachou K, Chatzikyrkou C,  Bozkaya H, Daleko GN, Manns M, Wedemeyer H. J Viral Hep 2012; 19: 387-95.

59- HBeAg-positive hepatitis delta: virologic patterns and clinical long-term outcome. Heidrich B, Serrano BC, Idilman Ri Kabaçam G, Bremer B, Raupach Bi Onder FO, Deterting K, Zacher BJ, Taranta A, Bozkaya H, Zachaou K, Tilmann HL, Bozdayi AM, Manns MP, Yurdaydin C, Wedemeyer H. Liver international 2012; 32: 1415-25

60- Pegylated interferon based treatment in patientswith  advanced liver disease due to  chronic delta hepatitis.Kabacam G, Dalekos GN, Cakaloglu Y, Zachou K, Bock T,  Erhardt A, Zeuzem S, Tabak F, Yalcın K, Bozdayi AM, Dienes HP, Bozkaya H, Manns M, Wedemeyer H, Yurdaydin C. Turk J Gastroneterol 2012; 23: 560-568

61- Genome-wide transcriptional reorganisation associated with senescent to immortality switch during human hepatocellular carcinogenesis. Yildiz G, Arslan Ergül A, Bagislar S, Konu O, Yuzugullu H, Gursoy Yuzugullu O, Ozturk N, Ozan C, Ozdag H, Erdal H, Karademir S, Sagol O, Mizrak D, Bozkaya H, Ilk HG, Ilk O, Bilen B, Cetin-Atalay R, Akar N, Ozturk M. Plos One 2013; 15: e64016

62- Role of immunoj-histochemistry for hepatitis delta and hepatitis B virus in hepatitis delta. Kabacam G, Wedemeyer H, Savas B, Keskin O, Delakos G, Tabak F, Idilman R, Erhardt A, Yalcin K, Bozdayi AM, Bozkaya H, Manns M, Dienes H, Yurdaydin C. Liver Int 2013; 12376

63- Manometric assessment of esophageal motor function in patients with primary biliary cirrhosis. Bektas M, Seven G, Idilman R, Yakut M, Doganay B, Kabacam G, Ustun Y, Korkut E, Kalkan C, Sahin G, Cetinkaya H, Bozkaya H, Yurdaydin C, Bahar K, Cinar K, Soykan I. Eur J Intern Med 2014 Feb 14

64-Tumor necrosis factor alpha, interleukin 10, interferon gamma and vitamine D receptor gene polymorphisms in patients with hepatitis delta. Karatayli SC, Ulger ZE, Ergul AA, Keskin O, Karataylı E, Albayrak R, Ozkan M, Idilman R, Yalcin K, Bozkaya H, Uzunalimoglu, O, Yurdaydin C, Bozdayi AM. J Viral Hepatitis 2014; 21: 297-304

65- Associatio between level of hepatitis D virus RNA at week 24 of pegylated interferon therapy and outcome. Keskin O, Wedemeyer H, Tüzün A, Zachou K, Deda X, Dalekos GN, Heidrich B, Pehlivan S, Zeuzem S, Yalçın K, Gürel S, Tabak F, Idilman R, Bozkaya H, Manns M, Yurdaydin C.

Clin Gastroenterol Hepatol. 2015 Dec;13(13):2342-49

66-Utility of endoscopy for diagnosis of barrett in a non-Western society: endoscopic and histopathologic correlation. Ege B, Dinç T, Yildiz BD, Balci Z, Bozkaya H.

Int Surg. 2015 Apr;100(4):720-5

ULUSLAR ARASI KİTAP BÖLÜMLERİ

1-Lok ASF, Bozkaya H, Ayola B. Hepatitis B virus pre-core/core gene mutants: epidemiology. In: Rizetto M, Purcell RH, Gerin JL, Verme G, eds. Viral Hepatitis and Liver Disease 1997.

2-Örmeci N, Gürler A, Tulunay Ö, Bozkaya H, Çetin F, Özden A, Uzunalimoğlu Ö.  Prevalence of helicobacter pylori in Behçet’s disease. In: Godeau F, Wechsler B, eds. Behçet’s Disease. Elsevier Science Publishers, 1993; pp 271-274.

ULUSLARARASI KONGRE KİTAPLARI

1- Cinar K, Bozdayi AM, Bozkaya H, Uzunalimoğlu Ö, Erekul S and Yurdaydin C. Possible mechanisms of the hepatoprotective effect of difluorormethylornitinhine on thioacetamide-induced fulminant hepatic failure in the rat. In: Yurdaydin C and Bozkaya H, eds. Advances in hepatic encephalopathy and metabolism in liver disease. Ankara University press, 1999; pp 59-66

2- Cinar K, Uzunalimoğlu Ö, Erekul S, Bozkaya H, Bozdayi AM, Yurdaydin C. N-acetylcystein in thioacetamide induced toxic hepatitis in rats. In: Yurdaydin C and Bozkaya H, eds. Advances in hepatic encephalopathy and metabolism in liver disease. Ankara University press, 1999; pp 453-459.

3- Celik T, Goren MZ, Gurdal H, Cinar K, Toruner M, Degim T, Uzbay IT, Bozkaya H, Yurdaydin CIs fatigue of cholestasis mediated by altered central serotonergic neurotransmission? Encephalopathy and nitrogen metabolism in liver failure. Kluwer academic publishers Eds: Jones EA, Meijer AJ, Chamuleau AFM. 2003; pp 165-171.

4- Gokturk S, Deda H, Bozkaya H, Yurdaydin C. Naloxane treatment of human hepatic encephalopathy. Encephalopathy and nitrogen metabolism in liver failure. Kluwer academic publishers Eds: Jones EA, Meijer AJ, Chamuleau AFM. 2003; pp 369-373

Katıldığı Mesleki Eğitimler, Kurslar ve Konferanslar

  • Birçok Ulusal makale ve bildiri ve çeşitli kongrelerde alınan ödüller mevcuttur

Mesleki Üyelikleri

  • EASL (European Association for the Study of Liver Disease)
  • TASL (Turkish Association for the Study of Liver Disease)
  • TGD (Turkish Gastroenterology Association)

CANLI DESTEK